Live
FierceBiotechASCO: Lilly exec points to ‘nutty’ 100% response rate for in vivo CAR-T as justifying Kelonia buyoutFierceBiotechASCO: Revolution Medicines confident in RAS leadership as rivals square upFierceBiotechASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%Endpoints News#ASCO26: Yes, Revolution Medicines' pancreatic cancer data are that goodEndpoints News#ASCO26: Summit, Akeso drug reduces death by 34% in China lung cancer studyBioPharma DiveAkeso, Summit drug extends survival in closely watched lung cancer trialBioPharma Dive‘Unprecedented’ Revolution data point to paradigm shift in pancreatic cancerScience Daily BiotechThe ocean's health may depend on a tiny microbe inside fishThermo FisherIs Thermo Fisher (TMO) Turning AI-Enabled Orbitraps Into a Durable Edge in Life Sciences Tools? - simplywall.stEndpoints News#ASCO26: Personalized cancer vaccines may help brain cancer patients live longerEndpoints News#ASCO26: Grail’s cancer blood test isn’t ready for widespread use, experts sayFierceBiotechIn next-gen IO race in NSCLC, BioNTech/BMS and Pfizer are divided on overall survival approach
FierceBiotech Apr 16, 2026

Aligos sells China rights to HBV drug to hepatology player Amoytop in $445M deal

Aligos sells China rights to HBV drug to hepatology player Amoytop in $445M deal

Original
Body unavailable. Use the original source.